FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer.

This article summarizes FDA decision-making and data supporting the approval of ribociclib.
PMID: 29437768 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - February 7, 2018 Category: Cancer & Oncology Authors: Shah A, Bloomquist E, Tang S, Fu W, Bi Y, Liu Q, Yu J, Zhao P, Palmby TR, Goldberg KB, Chang CJG, Patel P, Alebachew E, Tilley A, Pierce WF, Ibrahim A, Blumenthal GM, Sridhara R, Beaver JA, Pazdur R Tags: Clin Cancer Res Source Type: research